ASBrS 2019 Industry Symposia Content

As the field of hereditary cancer expands, genetic testing continues to become more important for personalized patient care. This presentation will give you answers to some of the most commonly asked questions from breast surgeons. We will discuss the role of breast surgeons in genetic testing, how to handle variants of unknown significance, contralateral breast cancer risk for both high and moderate risk genes, and the difference between direct-to-consumer testing and clinical genetic testing.

To view the presentation slides, click here: Sharpen your Skills: Hot Topics in Genetic Testing for Hereditary Breast Cancer.

For more information, visit www.ambrygenetics.com or contact Zach Jensen at zjensen@ambrygenetics.com.

Note: This satellite symposium is supported by Ambry Genetics, Inc., through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

GE Healthcare

Contrast Enhanced Mammography: A Simplified Way to Address the Advanced Imaging Needs of Your Patients

Learn from a breast surgeon about CESM and how she uses it in practice to meet the needs for neoadjuvant treatment, post-surgery surveillance and other issues. Overview and cases will be shared.

To learn more about CESM, click HERE.

For more information, contact Stacie Sands at Stacie.sands@ge.com.

Note: This satellite symposium is supported by GE Healthcare, through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Genomic Health, Inc.

Beyond TAILORx: Using Recurrence Score® Results in Loco-Regional Control, Node-Positive and Neoadjuvant Decisions

To view this presentation, click HERE.

Note: This satellite symposium is supported by Genomic Health, Inc., through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Genentech

Treatment Considerations for High Risk Patients with Early Breast Cancer

For more information, contact Erin Hays at EHays@medforce.net.

Note: This satellite symposium is supported by Genentech, through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Stryker

Breast Cancer Surgery Redefined: Novel Technologies and Techniques that Expand Indications for Nipple Sparing Mastectomy, Oncoplastic Surgery and Hidden Scar® Techniques

This symposium will discuss the advanced techniques, considerations and enabling technologies for Nipple Sparing Mastectomy, Oncoplastic surgery and Hidden Scar Techniques. With the emphasis on both the oncologic and psychosocial outcomes of breast cancer treatment, the keynote speakers will address how to expand indications for optimal techniques that prioritize survivorship.

For more information, contact Hannah LaBomascus at Hannah.labomascus@stryker.com.

Note: This satellite symposium is supported by Stryker, through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Albert Einstein College of Medicine

Virtual Cadaver Hands-On Workshop: Identifying Breast and Abdominal Planes for Surgical Infiltration to Manage Post-Surgical Pain

• Describe the opioid epidemic and associated adverse events with opioids
• Review the multimodal options utilized pre-op, inter-op and post-op in breast reconstruction surgery
• Identify the surgical anatomy targeting PECS I, II, III, serratus, classic tap, subcostal and rectus sheath blocks
• Demonstrate skill in ultrasound guided interscalene brachial plexus block and specific fascial plane block techniques via hands-on practice on live models, phantom stations

For more information, contact Stacy Atkinson, MS, CM, at 718-920-6674, or statkins@montefiore.org.

Note: This satellite symposium is supported by Pacira Pharmaceuticals through an educational grant provided to Albert Einstein College of Medicine. CME credits for this program will be provided by Albert Einstein College of Medicine. It is not part of the official program of the ASBrS*. This activity is free to all registered attendees. (*An independent grant from Albert Einstein College of Medicine was provided to the ASBrS in order to offer this satellite symposium during the 20th Annual Meeting.)

Cianna Medical, Inc., Powered by Merit Medical

Advanced Utilization of Wire-Free Technology from Biopsy to Surgery

For more information, click: www.merit.com/thinkwirefree

Learn how advanced applications of SCOUT® Radar Localization enable enhanced efficiency, precision and patient experience for placement at time of biopsy, localization prior to neoadjuvant therapy, and oncoplastic surgery.

Note: This satellite symposium is supported by Cianna Medical, Inc., Powered by Merit Medical, through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Hologic, Inc.

BioZorb® and a New Way to 5-day Radiation

For more information about the breakfast symposium, contact MedEd-BSH@hologic.com. For additional education opportunities, visit HologicED.com.

Note: This satellite symposium is supported by Hologic, Inc., through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

PeerView Institute

On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum

To view the presentation, CLICK HERE.

1. Describe the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC) specifically, and in breast cancer more broadly, including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies (eg, chemotherapies, other immunotherapies, PARP inhibitors and other targeted agents, surgery, radiation, etc.) that may enhance immunogenicity and improve outcomes
2. Discuss biomarkers that may have utility in guiding and refining clinical decisions regarding the selection of appropriate candidates for immune-based and other therapies in TNBC, and the nuances of testing for these biomarkers in practice
3. Analyze efficacy, safety, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including metastatic, locally advanced, and early-stage resectable disease
4. Integrate immune checkpoint inhibitors and/or other effective treatment modalities into management plans of patients with TNBC based on the latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, biomarker testing results, and patient needs/preferences

Tremendous advances have been made in the treatment of many other subtypes of breast cancer, but treatment of triple-negative breast cancer (TNBC) has remained challenging. However, recent developments suggest that we are on the brink of a new era in TNBC therapy that now brings the novel class of cancer immunotherapies to this population of patients. What is the most rational way and optimal setting to use of cancer immunotherapies? How can we maximize their benefits so that more patients with TNBC would benefit from them?

In this CME/MOC/CNE-accredited PeerView MasterClass symposium, our expert panel discusses the biologic rationale for the use of cancer immunotherapies in breast cancer in general and TNBC specifically, as well as evolving evidence supporting the use of immune checkpoint inhibitors in advanced/metastatic and early-stage resectable TNBC (including clinical trials focused on monotherapy approaches, combinatorial approaches with different chemotherapies, and combination or sequential strategies with targeted agents, different immunotherapies, vaccines, radiation, surgery, and other treatment modalities). Additionally, the panel will focus on patient/tumor evaluation and candidate selection for immunotherapy, using current and novel biomarkers to guide clinical decisions in early-stage and advanced disease, the importance of being aware of potential immune-related adverse events and how to diagnose/manage them, and the need for close collaboration among breast surgeons, oncologists, pathologists, and other professionals involved in the management of patients with breast cancer. Illustrative case studies and clinical scenarios during the Practicum segment will provide further guidance on strategies for educating patients and best practices for the use and integration of immunotherapies into the treatment arsenal for patients with TNBC in real-world, clinical practice settings.

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. This activity is supported by an independent educational grant from Merck & Co., Inc.

Note: This satellite symposium is supported by Merck & Co., Inc. through an independent educational grant provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. CME credits for this program will be provided by Medical Learning Institute, Inc. It is not part of the official program of the ASBrS*. This activity is free to all registered attendees. (*An independent grant from Medical Learning Institute, Inc. was provided to the ASBrS in order to offer this satellite symposium during the 20th Annual Meeting.)